Dr. Raza Bokhari, the Executive Chairman and CEO of Medicus Pharma (TSX-V:MDCX), discussed the company's recent milestone of submitting the phase two clinical protocol to the FDA during an interview with Steve Darling from Proactive. Medicus Pharma is a clinical-stage holding company listed on the Toronto Stock Exchange that specializes in identifying and investing in novel therapeutic assets, with a primary focus on advancing non-invasive treatments for skin cancers, particularly basal cell carcinoma.
Dr. Bokhari expressed his enthusiasm for the progress made since the fall of the previous year, highlighting the completion of a phase one trial and the initiation of a phase two trial in pursuit of FDA approval. He emphasized the company's strategy to accelerate through the FDA trial process, aiming for fast-track designation and eventual commercialization. Medicus Pharma's recent participation in the Biotech Showcase at the JP Morgan conference garnered positive feedback and attention. Furthermore, the company's expansion to the Frankfurt exchange aligns with its ambitious plans for a busy and productive 2024, with hopes of crossing borders and uplifting to NASDAQ.
As Medicus Pharma navigates these significant milestones, Dr. Bokhari reiterated the company's commitment to creating sustainable shareholder value and the exciting opportunities on the horizon in the field of non-invasive skin cancer treatments.